Peptide Vaccine Market Peptide Vaccine Clinical Pipeline Report 2020

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

1. Peptide Vaccine: A Prologue to Sub-Unit Vaccines
1.1 Introduction
1.2 Glimpse of Antiquity

2. Need of Peptide Vaccines
2.1 Why Peptides – More Desirable
2.2 Peptide Vaccines V/S Traditional Vaccines

3. Classification of Peptide Vaccines
3.1 On the Basis of Sources Obtained
3.2 On the Basis of Length
3.3 On the Basis of Epitopes

4. Designing & Production of Peptide Vaccine
4.1 Synthetic Peptide Vaccine
4.2 Selection of Peptide Antigen
4.3 Construction of Peptide Antigen
4.4 Chemical Synthesis of Peptide Vaccine
4.4.1 Solution Phase Synthesis (SPS)
4.4.2 Solid Phase Peptide Synthesis (SPPS)

5. Mechanism of Peptide Vaccine
5.1 Induction of Immune Response
5.1.1 Factors Affecting T-Cell Stimulation
5.1.2 Factors Affecting B-cell Stimulation
5.1.3 Factors Affecting T-helper Cells
5.2 Delivery System for Peptide Vaccines
5.2.1 Immunostimulatory Adjuvants
5.2.2 Vaccine Delivery System
5.3 Multiple Antigen Peptide System (MAP)
5.3.1 Use of MAP for Foot-and-Mouth Disease

6. Cancer Immunotherapy with Peptide Vaccine
6.1 Peptides as Tumor Antigens
6.2 Immunotherapy with Peptide Vaccination
6.3 Therapeutic Evaluation of Peptide Vaccine
6.3.1 Prostate Cancer
6.3.2 Breast Cancer
6.3.3 Gastric Cancer
6.3.4 Lung Cancer
6.3.5 Pancreatic Cancer

7. Global Peptide Vaccine Market Overview
7.1 Peptide Vaccine – Does have Long & Secure Future?
7.2 Peptide Patents Insights
7.3 Peptide Vaccine Pipeline Overview

8. Global Peptide Vaccine Market Dynamics
8.1 Accelerative Parameters
8.1.1 Peptidomics
8.1.2 Advances in Vaccine Research
8.1.3 Stronger Clinical Pipeline
8.1.4 Emergence of Biologics in Cancer Therapy
8.2 Commercialization Challenges & Modifications
8.2.1 Funding & Legal Issues
8.2.2 Designing & Manufacturing Challenges
8.2.3 Route of Administration
8.2.4 Peptide Pharmacodynamics & Pharmacokinetics

9. Global Peptide Vaccine Market Future Perspectives

10. Global Peptide Vaccine Clinical Pipeline by Company, Indication & Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III

11. Discontinued & Suspended Peptide Vaccine Clinical Pipeline by Company, Indication & Phase
11.1 No Development Reported
11.2 Discontinued
11.3 Market Withdrawal
11.4 Suspended

12. Competitive Landscape
12.1 AFFiRiS
12.2 AlerGenetica
12.3 Anergis
12.4 Antigen Express
12.5 Apitope Technology
12.6 Araclon Biotech
12.7 Artificial Cell Technologies
12.8 Benovus Bio
12.9 Bionor Pharma
12.10 Circassia
12.11 Celgene Corporation
12.12 Galena Biopharma
12.13 Immatics biotechnologies
12.14 Immune Design
12.15 ImmunoCellular Therapeutics
12.16 Invectys
12.17 ISA Pharmaceuticals
12.18 Lytix Biopharma
12.19 Medinet
12.20 Spotlight Innovation (Memcine Pharmaceuticals)
12.21 Merck Serono
12.22 OncoTherapy Science
12.23 Peptech
12.24 Peptinov
12.25 PeptiVir
12.26 Pharmasyntez
12.27 Renaptys Vaccines
12.28 Sumitomo Dainippon Pharma
12.29 TapImmune
12.30 Targovax
12.31 Vaxon Biotech

Download Report: https://www.kuickresearch.com/report-Global-Peptide-Vaccine-Market-&-Clinical-Pipeline-Outlook-2020.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.